Asgard Therapeutics Collaborates With Exothera to Advance AT-108 Into Clinical Trials

Overview

Asgard Therapeutics, a private biotech company focused on in vivo direct cell reprogramming for cancer immunotherapy, has chosen Exothera S.A. to develop the manufacturing processes and handle clinical production for its promising therapy, AT-108. Exothera, known for its advanced capabilities in nucleic acid and viral vector production, will support Asgard Therapeutics in developing the manufacturing process for AT-108. This includes developing analytical methods, producing GMP-grade materials, and handling aseptic filling.

About AT-108

• AT-108 is a novel off-the-shelf gene therapy aimed at triggering personalized and powerful immune responses against cancer. 
• It works by reprogramming cancer cells in the patient to transform into Type 1 Dendritic Cells (cDC1s), which are crucial for effective anti-tumor immunity. 
• These modified cells present the patient's unique cancer antigens to the immune system, prompting targeted and comprehensive anti-cancer responses.

Exothera's Facilities

• Exothera's extensive facilities and experience in viral vector-based biotherapeutics will play a key role in advancing AT-108 through clinical trials. 
• Their production capabilities, among the largest in Europe (15,000 m² – 161,500 ft²), will be vital in supporting the development of this therapy.

Asgard Therapeutics

Asgard Therapeutics, shared her enthusiasm about progressing to the process development stage and beginning CMC activities, saying, "We look forward to collaborating with the expert team at Exothera to advance our innovative AT-108 therapy towards clinical trials."

From Exothera

• • Exothera, stated, "We are proud to assist Asgard Therapeutics in bringing these innovative therapies to patients.” 
• With our extensive experience in the production of virus-based therapeutics, we are confident in our ability to support the successful progression to clinical phases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!